In December 2020, the NITAG following the referral from the Minister of Health recommended that Burkina Faso integrate the COVAX mechanism and prepare for the introduction of vaccines against COVID-19. Thus, a national plan for the deployment of vaccines and vaccination (NDVP) was developed based on the guidelines of the NITAG.
As part of the implementation of this plan, the country received one hundred and seventy-two thousand and eight hundred (172,800) doses of AZD1222 (Astra Zeneca) vaccines from the COVAX initiative, three hundred and two- one thousand four hundred (302,400) doses of Johnson & Johnson vaccine from Belgium, two hundred and sixty (260) doses of Johnson & Johnson vaccine from the French Embassy. On September 18, the country received four hundred thousand (400,000) doses of the SINOPHARM vaccine. In total, Burkina Faso has received eight hundred, seventy-five thousand, four hundred and sixty (875,460) doses of vaccines against COVID-19.
As of September 28, 2021, two hundred and forty-seven thousand six hundred and seventy-one (247,671) people have been vaccinated, including twenty thousand, eight hundred and thirty-six (20,836) received two doses of Astra Zenecca and 161,275 for the Johnson & Johnson vaccine.
Also, in view of the evolution of the epidemiological situation of the disease marked by the appearance of new variants and the challenges faced by vaccination, the acquisition of other vaccines, the NITAG met from 28 to 30 September 2021 to revise the recommendation note on the introduction of the COVID-19 vaccine in Burkina Faso.
- Recommendation
- Africa
- Burkina Faso
- COVID-19
